124 research outputs found
Association between trial registration and positive study findings: cross sectional study (Epidemiological Study of Randomized Trials—ESORT)
Objective To assess whether randomised controlled trials (RCTs) that were registered were less likely to report positive study findings compared with RCTs that were not registered and whether the association varied by funding source.
Design Cross sectional study.
Study sample All primary RCTs published in December 2012 and indexed in PubMed by November 2013. Trial registration was determined based on the report of a trial registration number in published RCTs or the identification of the trial in a search of trial registries. Trials were separated into prospectively and retrospectively registered studies.
Main outcome measure Association between trial registration and positive study findings.
Results 1122 eligible RCTs were identified, of which 593 (52.9%) were registered and 529 (47.1%) were not registered. Overall, registration was marginally associated with positive study findings (adjusted risk ratio 0.87, 95% confidence interval 0.78 to 0.98), even with stratification as prospectively and retrospectively registered trials (0.87, 0.74 to 1.03 and 0.88, 0.78 to 1.00, respectively). The interaction term between overall registration and funding source was marginally statistically significant and relative risk estimates were imprecise (0.75, 0.63 to 0.89 for non-industry funded and 1.03, 0.79 to 1.36 for industry funded, P interaction=0.046). Furthermore, a statistically significant interaction was not maintained in sensitivity analyses. Within each stratum of funding source, relative risk estimates were also imprecise for the association between positive study findings and prospective and retrospective registration.
Conclusion Among published RCTs, there was little evidence of a difference in positive study findings between registered and non-registered clinical trials, even with stratification by timing of registration. Relative risk estimates were imprecise in subgroups of non-industry and industry funded trials
Evidence of the contribution of the X chromosome to systemic sclerosis susceptibility: Association with the functional IRAK1 196Phe/532Ser haplotype
n/
Trace amine-associated receptor 1 (TAAR1) agonists for psychosis: protocol for a living systematic review and meta-analysis of human and non-human studies
Background: There is an urgent need to develop more effective and
safer antipsychotics beyond dopamine 2 receptor antagonists. An
emerging and promising approach is TAAR1 agonism. Therefore, we
will conduct a living systematic review and meta-analysis to synthesize and triangulate the evidence from preclinical animal experiments and
clinical studies on the efficacy, safety, and underlying mechanism of
action of TAAR1 agonism for psychosis.
Methods: Independent searches will be conducted in multiple
electronic databases to identify clinical and animal experimental
studies comparing TAAR1 agonists with licensed antipsychotics or
other control conditions in individuals with psychosis or animal
models for psychosis, respectively. The primary outcomes will be
overall psychotic symptoms and their behavioural proxies in animals.
Secondary outcomes will include side effects and neurobiological
measures. Two independent reviewers will conduct study selection,
data extraction using predefined forms, and risk of bias assessment
using suitable tools based on the study design. Ontologies will be
developed to facilitate study identification and data extraction. Data
from clinical and animal studies will be synthesized separately using
random-effects meta-analysis if appropriate, or synthesis without
meta-analysis. Study characteristics will be investigated as potential
sources of heterogeneity. Confidence in the evidence for each
outcome and source of evidence will be evaluated, considering the
summary of the association, potential concerns regarding internal
and external validity, and reporting biases. When multiple sources of
evidence are available for an outcome, an overall conclusion will be
drawn in a triangulation meeting involving a multidisciplinary team of
experts. We plan trimonthly updates of the review, and any
modifications in the protocol will be documented. The review will be
co-produced by multiple stakeholders aiming to produce impactful
and relevant results and bridge the gap between preclinical and
clinical research on psychosis
Trace amine-associated receptor 1 (TAAR1) agonists for psychosis:protocol for a living systematic review and meta-analysis of human and non-human studies
BACKGROUND: There is an urgent need to develop more effective and safer antipsychotics beyond dopamine 2 receptor antagonists. An emerging and promising approach is TAAR1 agonism. Therefore, we will conduct a living systematic review and meta-analysis to synthesize and triangulate the evidence from preclinical animal experiments and clinical studies on the efficacy, safety, and underlying mechanism of action of TAAR1 agonism for psychosis.METHODS: Independent searches will be conducted in multiple electronic databases to identify clinical and animal experimental studies comparing TAAR1 agonists with licensed antipsychotics or other control conditions in individuals with psychosis or animal models for psychosis, respectively. The primary outcomes will be overall psychotic symptoms and their behavioural proxies in animals. Secondary outcomes will include side effects and neurobiological measures. Two independent reviewers will conduct study selection, data extraction using predefined forms, and risk of bias assessment using suitable tools based on the study design. Ontologies will be developed to facilitate study identification and data extraction. Data from clinical and animal studies will be synthesized separately using random-effects meta-analysis if appropriate, or synthesis without meta-analysis. Study characteristics will be investigated as potential sources of heterogeneity. Confidence in the evidence for each outcome and source of evidence will be evaluated, considering the summary of the association, potential concerns regarding internal and external validity, and reporting biases. When multiple sources of evidence are available for an outcome, an overall conclusion will be drawn in a triangulation meeting involving a multidisciplinary team of experts. We plan trimonthly updates of the review, and any modifications in the protocol will be documented. The review will be co-produced by multiple stakeholders aiming to produce impactful and relevant results and bridge the gap between preclinical and clinical research on psychosis.PROTOCOL REGISTRATION: PROSPERO-ID: CRD42023451628.</p
Low CD4/CD8 T-Cell Ratio Associated with Inflammatory Arthropathy in Human T-Cell Leukemia Virus Type I Tax Transgenic Mice
Human T-cell leukemia virus type I (HTLV-1) can cause an aggressive malignancy known as adult T-cell leukemia/lymphoma (ATL) as well as inflammatory diseases such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). A transgenic mouse that expresses HTLV-1 Tax also develops T-cell leukemia/lymphoma and an inflammatory arthropathy that resembles rheumatoid arthritis. The aim of this study was to identify the primary T-cell subsets involved in the development of arthropathy in Tax transgenic mice. mRNA was strong in the spleen and joints of arthropathic mice, with a 40-fold increase compared with healthy transgenic mice.Our findings reveal that Tax transgenic mice develop rheumatoid-like arthritis with proliferating synovial cells in the joints; however, the proportion of different splenic T-cell subsets in these mice was completely different from other commonly used animal models of rheumatoid arthritis. The crucial T-cell subsets in arthropathic Tax transgenic mice appear to resemble those in HAM/TSP patients rather than those in rheumatoid arthritis patients
Erratum to: Methods for evaluating medical tests and biomarkers
[This corrects the article DOI: 10.1186/s41512-016-0001-y.]
- …